Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886307 | 1.00 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL3885293 | 0.90 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL3883788 | 0.90 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL3886310 | 0.86 | ADRB2 (0.41) | ADRB2ADRB1ADRB3ALDH1A1MEN1 | |
| SCHEMBL3889490 | 0.86 | ADRB2 (0.41) | ADRB2ADRB1ADRB3ALDH1A1MEN1 | |
| SCHEMBL1882948 | 0.80 | ADRB2 (0.39) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL1891000 | 0.80 | ADRB2 (0.39) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL1886217 | 0.78 | ADRB2 (0.36) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL1886218 | 0.77 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL3891100 | 0.76 | ADRB2 (0.41) | ADRB2ADRB1ADRB3ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566738-B2 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | ASS1, APEH, ACMSD | ADRB2 3867/4885ADRB1 3477/4885ADRB3 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.